Plans by NICE to start charging pharma companies for appraising their medicines are to be ‘paused’ in order to allow the government to complete its life sciences strategy.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
